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Heterozygous, germline nonsense mutations in AXIN2 have been reported in two families with oligodontia and
colorectal cancer (CRC) predisposition, including anAXIN2 1989GNAmutation. SomaticAXIN2mutations predicted to
generate truncated AXIN2 (trAXIN2) proteins have been reported in some CRCs. Our studies of cells from an AXIN2
1989GNAmutation carrier showed that the mutant transcripts are not significantly susceptible to nonsense-mediated
decay and, thus, could encode a trAXIN2 protein. In transient transfection assays, trAXIN2 was more abundant than
wild-type AXIN2 protein, and in contrast to AXIN2, glycogen synthase kinase 3β inhibition did not increase trAXIN2
levels. Like AXIN2, the trAXIN2 protein interacts with β-catenin destruction complex proteins. When ectopically
overexpressed, trAXIN2 inhibits β-catenin/T-cell factor–dependent reporter gene activity and SW480 CRC cell colony
formation. These findings suggest the trAXIN2 protein may retain some wild-type functions when highly expressed.
However, when stably expressed in rat intestinal IEC-6 cells, the trAXIN2 protein did not match AXIN2’s activity in
inhibiting Wnt-mediated induction of Wnt-regulated target genes, and SW480 cells with stable expression of trAXIN2
but not AXIN2 could be generated. Our data suggest the AXIN2 1989GNA mutation may not have solely a loss-of-
function role in CRC. Rather, its contributionmay depend on context,with potential loss-of-functionwhenAXIN2 levels
are low, such as in the absence of Wnt pathway activation. However, given its apparent increased stability in some
settings, the trAXIN2 proteinmight have gain-of-function in cells with substantially elevatedAXIN2 expression, such as
Wnt pathway–defective CRC cells.
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There are two AXIN proteins—AXIN1 and AXIN2. AXIN2 has
been termed conductin or Axil in the case of the mouse or rat
orthologs, respectively. A primary function of AXIN1 is in the
assembly of the so-called “β-catenin destruction complex”, which
plays a key role in regulating the pool of β-catenin that functions in
Wnt pathway signaling and β-catenin/T-cell factor (TCF)–regulated
gene expression. Activation of the Wnt signaling pathway and
dysregulation of β-catenin protein levels and localization are
commonly presumed to be critical events in colorectal cancer
(CRC) development. Because AXIN1 is a negative regulator of
β-catenin, AXIN1 has been classically thought of as a tumor
suppressor protein. Studies in selected CRC and hepatocellularcarcinoma cell lines showed that ectopic expression of AXIN1 can
inhibit cell growth in vitro, reduce total β-catenin protein levels, and
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mouse model in whichAxin1 is conditionally inactivated in hepatocytes
manifests an increased risk of hepatocellular cancer [2], further evidence
of a role for AXIN1 as a tumor suppressor factor.
AXIN2 was initially identified through yeast two-hybrid experi-
ments with β-catenin and glycogen synthase kinase 3β (GSK3β) and
named for its homology to AXIN1 [3,4]. Like AXIN1, AXIN2
appears to act as a scaffold factor in the β-catenin destruction
complex, and the two AXIN proteins have extensive similarity in
several domains [4]. The two AXIN proteins are considered
functionally equivalent, as an Axin2 cDNA inserted into the Axin1
mouse locus rescues the Axin1-null lethality [5]. However, while
constitutional loss of Axin1 is lethal in the mouse during
embryogenesis at e9.5 [6,7], mice carrying homozygous null
mutations in Axin2 are viable and fertile, with a mild skull
abnormality, indicating that the two genes are not fully redundant
in vivo [8]. This difference in phenotypes likely reflects the differential
expression patterns of the two genes; while AXIN1 is ubiquitous in
various tissues [9], AXIN2 shows a more restricted developmental and
cell-type–specific expression pattern [4]. Additionally, AXIN2, but
not AXIN1, is a major transcriptional target of β-catenin–dependent
Wnt signaling, and AXIN2 expression is significantly elevated in
cancers with Wnt pathway mutations [10–12]. Because AXIN2 is
positively regulated by upstream Wnt- and β-catenin–dependent
signals and because the AXIN proteins are the least abundant members
of the β-catenin destruction complex [13], control of AXIN2 protein
levels could be a key negative feedback mechanism for the regulation of
Wnt/β-catenin signaling in cells.
Mutations that lead to aberrant Wnt pathway activation are found
in roughly 90% of sporadic CRCs [14]. Germline, inactivating
mutations in the adenomatous polyposis coli (APC) gene underlie the
inherited CRC predisposition syndrome familial adenomatous
polyposis [15], and APC somatic mutations are present in about
70% to 80% of apparently sporadic CRCs [14]. Dysregulation of the
Wnt pathway is believed to be an important first step in the genesis of
CRCs [16], and this key role is also well supported by work in mouse
models harboring mutations in Apc [17,18]. Akin to a key function of
the AXIN proteins, APC is thought to have a crucial role in the
assembly of the β-catenin destruction complex, and APC defects lead
to increased levels of “free” β-catenin that drives cell survival and
proliferation, in part through effects on β-catenin/TCF-regulated
genes. While the most common mode of Wnt pathway dysregulation
in CRC is abrogation of wild-type APC function, other Wnt pathway
mutations are seen in CRCs [14]. Indeed, mutations in both AXIN1
and AXIN2 have been reported in association with CRC, although
the functional significance in cancer of most reported AXIN1/2
mutations is uncertain [19]. In two unrelated kindreds with
autosomal dominant oligodontia (the congenital absence of six or
more adult teeth) and colorectal neoplasia (variable phenotypes,
including oligo/attenuated polyposis and CRC), affected individuals
have been found to carry heterozygous germline mutations predicted to
prematurely truncate the AXIN2 open reading frame [20,21]. To better
understand the role of AXIN2 defects in CRC, we have studied one of
these germline AXIN2 mutations—the 1989GNA allele that leads to a
premature stop at codon 663 (W663X)—and the truncated AXIN2
(trAXIN2) protein product predicted to be expressed from the allele.We
present studies and data below that indicate that the trAXIN2 protein
may have potentially complex and context-dependent effects that
depend, in part, on the levels of trAXIN2 expression.Materials and Methods
Expression Constructs and Cell Culture
A wild-type AXIN2 cDNA was generated by polymerase chain
reaction (PCR)–based approaches, using total RNA isolated from the
DLD-1 cell line (ATCC CCL-221). The identity of the AXIN2
wild-type cDNA sequence was confirmed by standard sequencing
approaches. A trAXIN2 sequence, modeling that seen in the 1989GNA
allele, was made by site-directed mutagenesis of the wild-type AXIN2
construct, and the wild-type AXIN2 and trAXIN2 sequences were
subcloned into the following expression constructs: pPGS-CMV-Cite-
Neo for retroviral expression, pCMV-3Tag for FLAG-tagged expres-
sion, pCS2+MT for myc-tagged expression, and pEYFP-C1 for
EYFP-tagged expression. A human AXIN1 cDNA (isoform a) was
generated previously by Janet Leung and cloned into pcDNA3.1 with
an N-terminal FLAG-tag and C-terminal myc-tag. The sequence was
confirmed by standard sequencing techniques. A β-catenin S33Y
expression construct has been previously described [22]. All cells were
cultured under sterile conditions at 37°C in 5% CO2. The HEK293T,
RKO (ATCC CCL-2577), and SW480 (ATCC CCL-228) cell lines
were cultured in Dulbecco's modified Eagle's medium (Gibco, Grand
Island, NY) with the addition of 10% FBS (Fisher Pittsburgh, PA) and
1% penicillin/streptomycin (Gibco). IEC-6 cells (ATTC CRL-1592)
were grown in Dulbecco's modified Eagle's medium (Gibco) with the
addition of 10%FBS (Fisher), 1%penicillin/streptomycin (Gibco), and
0.1 U/ml recombinant human insulin (Gibco). For transfection-based
studies, cells were transfected in 6-well plates or 12-well plates at 50% to
80% confluence, using 1 to 2 μg of total DNA per well with the
TransIT-LT1 transfection reagent (Mirus, Madison, WI).Characterization of Endogenous AXIN2 Transcripts in a
Heterozygous Carrier of the Mutant 1989GNA Allele
After obtaining informed consent, peripheral blood was drawn and
peripheral blood lymphocytes (PBLs) were isolated using Ficoll-Hypaque
separation. The buffy coat layer was removed and plated onto polystyrene
tissue culture dishes for 2 hours at 37°C to allow for adherence depletion
of monocytes. PBLs were cultured in RPMI 1640 (Gibco) supplemented
with L-glutamine (Gibco), 10%FBS (Fisher), 1%penicillin/streptomycin
(Gibco), 1% Hepes (Gibco), 0.5% β-mercaptoethanol (Gibco), 5 μg/ml
PHA-M (Sigma, St. Louis, MO), and 7 ng/ml interleukin-2 (Sigma).
PBLs were cultured for 48 hours and then treated with 5 μM BIO (No.
13123; Cayman Chemical, Ann Arbor, MI) or DMSO for 18 hours.
Total RNAwas isolated using TRIzol, and cDNAwas generated with the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Carlsbad, CA). Genomic DNA (gDNA) was isolated from PBLs by
boiling the cells in 50 mM NaOH followed by neutralization with 1 M
Tris (pH 8.0). PCR to specifically amplify gDNA or cDNA was done
using Taq polymerase (Promega, Madison, WI). Bulk PCR products
were gel-extracted and sequenced. PCR products from gDNA and cDNA
were TOPO subcloned, using the pCR2.1 TOPO cloning vector
(Invitrogen, Grand Island, NY). Single TOPO clones were then isolated
and sequenced to confirm the 1989GA genotype and the presence of the
AXIN2 3′untranslated region (UTR). The primers used to amplify
AXIN2 gDNA are given as follows: forward primer located in intron 5
(CCGACTTGCTGAATTGTCTG) and reverse primer located in
intron 7 (AAGCAGCAGCTTACTCATCCA). The primers used to
amplify AXIN2 cDNA are given as follows: forward primer located in
exon 6 (GGGAGGAAGGAGACAGGTCGC) and reverse primer
located in the AXIN2 3′UTR (CAAAGCCAGACCCCAGGG).
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HEK293T cells were transfected with relevant plasmids. Twenty-
four hours after transfection, cells were treated with 100 ng/ml Wnt3a
(R&DSystems,Minneapolis,MN) for 8 hours. Cells were then lysed in
Passive Lysis Buffer (Promega), and luciferase activity was analyzed
using the Promega Luciferase Assay Reagent and a GloMax
Luminometer (Promega). The TOPFlash construct has been described
previously [23]. The luminescence of each sample was normalized to
total protein by Bicinchoninic acid assay (Pierce, Grand Island, NY).
Relative luminescence values were compared using a t test to determine
statistical significance.
Quantitative PCR
For Wnt target gene analysis, IEC-6 cells were transduced with
AXIN2 or trAXIN2 retroviral constructs and then grown under
G418 selection to generate stable polyclonal cell lines. To assess
effects of stable AXIN2 or trAXIN2 expression on Wnt-mediated
induction of β-catenin/TCF target genes, 100,000 stably transduced
IEC-6 cells were plated onto a 6-cm dish. Twenty-four hours after
plating, the cells were treated with 200 ng/ml recombinant Wnt3a
(ProSci, San Diego, CA) to induce target gene expression or with
phosphate-buffered saline as a control. After 16 hours of induction,
RNA was collected by TRIzol extraction, cDNA synthesized, and
target genes analyzed by quantitative PCR (qPCR) using the primers
shown in Table 1. For quantification of AXIN2 or trAXIN2
(1989GNA) transcripts in ectopic expression assays, HEK293T cells
were transfected in six-well dishes with 2 μg of FLAG-tagged
expression constructs. At 24 hours after transfection, RNA was
isolated for analysis by qPCR. Ectopic transcripts were quantified by
PCR-based detection with primers for the FLAG sequence in the
AXIN2/trAXIN2 constructs.
Immunoprecipitation and Immunoblot Studies
Cells were transfected with plasmids using TransIT-LT1 (Mirus) or
Fugene-HD (Promega). Total protein was extracted using RIPA buffer,
followed by immunoprecipitation (IP) with the indicated antibody and
protein A/G agarose and 200 μg of total cellular protein. Proteins were
eluted from agarose by boiling in Laemmli buffer and analyzed by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis and immu-
noblot (IB). β-Catenin IPs were performed following a 5-hour
treatment with 10 μM of the proteasome inhibitor, MG132 (Cayman
Chemical). The following antibodies were used for IB analysis:
α-AXIN2 (Cell Signaling Technology, 76G6, Danvers, MA),
α-FLAG (Sigma, M2), α-myc (Sigma, C3956), α-total β-cateninTable 1. qPCR Primers for Wnt Target Gene and AXIN2/trAXIN2 Transcript Quantification
Gene Primer Sequence
U6 F—GTGCTCGCTTCGGCAGCACATAT
R—AAAAATATGGAACGCTTCACGAA
Axin2 F—CTCTAACGCTAGGCGGAATG
R—CCAGAAGTCCAGGGTATCCA
Lgr5 F—GCTGCCAAATTGTTGGTTTT
R—CAGGCTAGAAAGGGGAGCTT
Irs1 F—CCAGAAGCAACCAGAGGA
R—CCATGAGTTAAAAAGGAGGAT
Nkd1 F—AGGACGACTTCCCCCTAGAA
R—TGCAGCAAGCTGGTAATGTC
β-actin F—GCCTTCCTTCTTGGGTATGG
R—GCCTGGGTACATGGTGGT
FLAG F—AAGGACGATGATGACAAGGACTACA
R—TCCGGGAGGCAAGTCACCAA(BD Transduction Laboratories, Franklin Lakes, NJ), and α-β-actin
(Sigma, AC-15), and for IP: α-FLAG (Sigma, F7425) and α-myc (as
above). For protein stabilization studies, HEK293T cells were plated
onto a six-well dish and transfected at 70% to 90% confluence with
2 μg of FLAG-tagged proteins. Six hours after transfection, each well
was split into four wells of a six-well plate. Twenty-four hours
post-transfection, the cells were treated with DMSO, 100 nM okadaic
acid (OA; Cell Signaling Technology, No. 5934), 1 μMBIO, or both.
Cells were collected for IB analysis after 6 hours of inhibitor treatment.
XAV939 (Cayman Chemical) treatment was performed using the
indicated concentrations, and cells were collected for IB analysis after 24
hours of inhibitor treatment. Protein quantification was estimated
relative to β-actin using the ImageJ software [24].
CRC Cell Line Colony Formation Assays and Stable Cell Lines
CRC cells were transfected with vector, AXIN2, or trAXIN2
pCMV-3Tag expression constructs, which contain aNeomycin resistance
cassette. Twenty-four hours post-transfection, cells were counted, plated
in triplicate onto 24-well dishes, and grown under selection in 250 μg/ml
G418. RKO cells were plated at a density of 5000 cells per well. SW480
cells were plated at a density of 1000 cells per well. After 21 days, colonies
were fixed in 4% paraformaldehyde, stained with crystal violet, and
counted. Colony formation was performed in triplicate and repeated in
three independent transfections. Colony numbers were analyzed using a
t test to compare AXIN2 or trAXIN2 transfections to vector-only colony
number. In parallel studies, G418-resistant SW480 colonies were
harvested after 14 days of selection following transfection with empty
vector, AXIN2, or trAXIN2 pCMV3Tag expression constructs, and
protein lysates were prepared for IB studies, as above.
Results
The Sequence of the 1989GNA AXIN2 Mutant Allele Does Not
Generate Novel Splicing Motifs
Our initial efforts sought to determine if the AXIN2 1989GNA
mutant allele contained a novel sequence motif that might promote
altered splicing of AXIN2 transcripts. The 1989GNA sequence
change does not introduce a novel consensus splice donor or acceptor
element into the exon where it is located (exon 7 of AXIN2). Further
studies were undertaken using SplicePort [25] (spliceport.cbcb.umd.
edu/) to analyze the gDNA sequence of the 1989GNA and wild-type
AXIN2 alleles from intron 5 to exon 8 for potential splice recognition
elements. SplicePort analysis found no changes in the predicted splice
sites for the 1989A allele (Figure 1A). Exploration of the 1989GNA
and wild-type AXIN2 alleles with an exonic splicing enhancer
prediction program, ESEfinder [26,27] (rulai.cshl.edu/cgi-bin/tools/
ESE3/esefinder.cgi), found that the A allele does not disrupt any
predicted endogenous exonic splicing enhancers (ESEs) but does
encode an additional splicing factor 1 (SF1) ESE (Figure 1B), which,
if of any consequence, might be expected to favor inclusion of exon 7
in transcripts, consistent with the notion that the 1989GNA AXIN2
variant allele likely does not generate variant AXIN2 transcripts.
Mutant AXIN2 1989GNA Transcripts are Detected in a
Heterozygous Carrier
To address the possibility that nonsense-mediated degradation
(NMD) might reduce the levels of the 1989GNA transcripts, we
examined lymphocytes from the proband of Marvin et al. [21]. PBLs
were isolated from whole blood and briefly cultured in vitro before
RNA isolation. NMD of transcripts can result from the presence of a
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Figure 1. Analysis of AXIN2 gDNA and transcripts from a heterozygous 1989GNA allele carrier and the predicted AXIN2 truncated protein
expressed. (A) The 1989GNA allele does not generate new splice elements. The sequences of the AXIN2 1989G (wild-type) and 1989A
(mutant) alleles were analyzed using the SplicePort prediction algorithm. On the basis of the DNA sequence analysis, the positions of the
predicted splice acceptor and donor positions in the wild-type and mutant AXIN2 alleles are indicated, with no new splice sites predicted
in themutant AXIN2 allele. The actual splice sites surrounding exon 7 are denoted with an asterisk. (B) The exonic splicing enhancer factor
finder (ESEfinder) prediction identified one new predicted exon splicing enhancer factor binding site for SF1 binding in the 1989A allele.
The number of each type of potential serine/arginine-rich (SR) factor binding motifs found in the AXIN2 1989G and 1989A alleles is
indicated at the left. At the right, the SF1 consensus binding sequence motif is shown, with the corresponding sequences of the 1989G
and A alleles, indicating the new consensus site match for the “A” allele. (C) Sequencing analysis of PCR products for the relevant region
of AXIN2 exon 7 gDNA (gDNA) sequences in control DLD-1 CRC cells and (D) proband PBL samples. (E) Sequencing analysis of bulk PCR
products from proband PBL cDNA identifies transcripts from both the wild-type “G” and mutant “A” AXIN2 alleles. (F) A schematic
diagram of the location of the presumptive AXIN2 protein interaction domains [AXIN2 domains predicted to interact with TNKS
(tankyrase), APC, GSK3, β-catenin] and DIX dimerization motif, as well as the location of the 1989GNA (W663X) nonsense mutation.
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polyadenylation signal for a given mRNA. NMD is triggered during
the pioneering round of translation, when the exon junction proteins
are removed from an mRNA transcript. To enhance the levels of
AXIN2 transcripts in the cultured PBLs, the cells were treated with
BIO, a GSK3β inhibitor that mimics to some degree the effects of
activating Wnt ligands and increases the expression of Wnt target
genes, including AXIN2 [28]. Total RNA and gDNA were then
isolated from cells, cDNA was generated from total RNA, and the
sequences immediately surrounding the 1989GNA allele were PCR
amplified from both cDNA and gDNA. These bulk PCR products
were directly sequenced as well as subcloned to detect the presence of
wild-type and mutant alleles. The 1989GNA allele was confirmed in
gDNA from the proband and was absent in gDNA from the control
DLD-1 CRC cell line (Figure 1, C and D). Sequencing of the bulk
PCR products obtained from cDNA templates demonstrated that the
1989GNA allele was present at roughly equivalent levels to that of the
wild-type allele (Figure 1E ). To confirm these findings, individually
subcloned PCR products from gDNA and cDNA were sequenced,confirming that both wild-type and mutant AXIN2 transcripts were
present in PBLs. These findings indicate that AXIN2 transcripts in
PBLs of a 1989GNA mutation carrier do escape NMD, and the
transcripts would be expected to generate a truncated (trAXIN2)
protein product of 662 amino acids (Figure 1F ). The studies of
mutation carrier cDNAs did not uncover alternatively spliced
transcripts arising from the 1989GNA mutation.
The trAXIN2 Protein is More Abundant than Wild-Type
AXIN2 Protein in Transient Transfection-Based Studies
In transient transfection-based studies in HEK293T cells, the
ectopically expressed trAXIN2 protein was present at higher levels than
the wild-type AXIN2 protein (Figure 2, A and B). These findings were
true not only for the FLAG–epitope-tagged version of trAXIN2 but also
for ectopically expressed myc–epitope-tagged and untagged versions of
trAXIN2 (below and data not shown). Reverse transcription (RT)–
PCR–based studies revealed no significant differences in AXIN2
transcript levels between HEK293T cells transfected with the wild-type
AXIN2 or trAXIN2 expression constructs (Figure 2B).
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by GSK3β phosphorylation and protein phosphatase 2A (PP2A)
dephosphorylation [29,30]. The predicted GSK3β phosphorylation
sites in AXIN1 are conserved in AXIN2 (Figure 2C ). Hence, AXIN2
may be subject to GSK3β phosphorylation-mediated stabilization. The
PP2A interaction domain in AXIN1 has been mapped to a region of
approximately 200 amino acids in the carboxyl-terminal half of the
protein [31]. Assuming PP2A might also interact directly with AXIN2,
the trAXIN2 protein might be predicted to lack the PP2A interaction
motif, or it may fold in a way as to preclude PP2A interaction. To test
the effects of GSK3β and PP2A activity on the wild-type AXIN2 and
trAXIN2 proteins, we employed the GSK3β inhibitor, BIO [28], and
the PP2A inhibitor, OA [32], for studies of effects on the ectopically
expressed proteins in cells. As might be predicted from prior studies of
the effects of GSK3β or PP2A inhibition on AXIN1 levels, treatment of
transfected HEK293T cells with BIO reduced the levels of the AXIN2
protein, andOA treatment increased AXIN2 protein levels (Figure 2D).
The levels of the trAXIN2 were unchanged by BIO treatment,
suggesting that the stability of the trAXIN2 protein is not regulated by a
GSK3β-dependent mechanism (Figure 2D). However, like wild-type
AXIN2, the trAXIN2 protein is stabilized by OA treatment. AnotherA
C
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Figure 2. Analysis of AXIN2 and trAXIN2 protein abundance and reg
inhibitors of GSK3β, PP2A, and tankyrase on AXIN2 expression. (A) Th
relative to wild-type AXIN2. HEK293T cells were transfected with equa
and RNA were collected for analysis. An IB from protein lysates was pr
two constructs, with AXIN2 and trAXIN2 proteins detected by electro
FLAG-epitope. (B) Quantification of ectopically expressed AXIN2 transc
primers in the FLAGsequence and protein levels of AXIN2protein, based
relevant portion of the AXIN1 and AXIN2 protein sequences are sh
highlighted. (D) IB analysis of AXIN2 and trAXIN2 expression in transien
trAXIN2 proteins, following a 6-hour BIO and/or OA treatment, with “−
longer exposures of the IBs are shown. (E) HEK293T cells were co-tran
and then treated with increasing doses of XAV939, a tankyrase inhibito
analysis to detect the ectopically expressed AXIN2 and trAXIN2 proteinmechanism regulating the AXIN2 protein levels is polyADP-ribosylation
(PARsylation), with PARsylation leading to AXIN2 degradation through
ubiquitin ligation- and proteasome-dependent mechanisms [33].
Treatment of HEK293T cells ectopically expressing both AXIN2 and
trAXIN2 with XAV939, a small molecule inhibitor of tankyrase-
mediated PARsylation of AXINproteins, yielded data suggesting that the
wild-type AXIN2 protein was not significantly more sensitive to
PARsylation-mediated degradation than trAXIN2 (Figure 2E ).
The trAXIN2 Protein Retains Interactions with Components of
the β-Catenin Destruction Complex
The trAXIN2 protein, arising from the 1989GNA allele, lacks the
protein-encoding sequences from the last three AXIN2 exons, including
the so-called disheveled and AXIN (DIX) domain. The DIX domain is a
dimerization motif found in the carboxyl-terminal regions of both
AXIN1 and AXIN2 [9,34,35]. Lacking a DIX domain, the trAXIN2
protein would be predicted to be unable to dimerize with AXIN proteins,
which might affect the formation of the β-catenin destruction complex
[36–38]. Expression constructs encoding FLAG- or myc-epitope–tagged
AXIN2 and trAXIN2 cDNAs were co-transfected into HEK293T cells,
and the interaction between the AXIN2 and trAXIN2 proteinsE
ulation in transient transfection assays in HEK293T and effects of
e trAXIN2 protein is expressed at increased levels in HEK293T cells
l molar amounts of the AXIN2 or trAXIN2 expression vectors. Protein
epared from three separate transfection experiments for each of the
chemiluminescence (ECL)-based IBs with an antibody against the
ripts in the transfected HEK293T cells by quantitative RT-PCR using
on IB analyses relative to β-actin levels, using ImageJ software. (C) A
own, with potential GSK3β phosphorylation sites in the proteins
tly transfected HEK293T cells ectopically expressing the full-length or
” indicating no treatment and “+” indicating treatment. Shorter and
sfected with FLAG-tagged AXIN2 and trAXIN2 expression constructs
r, for 24 hours after transfection, before preparing protein lysates. IB
s was carried out with an anti-FLAG antibody.
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epitope-tagged AXIN2 wild-type and trAXIN2 proteins was studied, and
the levels of trAXIN2 proteins with either the FLAG- or themyc-tag were
higher than those for the corresponding epitope-tagged wild-type AXIN2
proteins (Figure 3A). Unexpectedly, the trAXIN2 protein was found to
immunoprecipitate with both AXIN2 and trAXIN2 (Figure 3B, upper),
in ratios largely representative of protein expression levels in the cells
(Figure 3A). However, when the IP was carried out with the anti-myc
antibody and the trAXIN2-myc protein, some reduction was seen in the
amount of AXIN2-FLAG protein recovered as compared to the IP with
anti-myc antibody and AXIN2-myc (Figure 3B). Overall, the exper-
iments imply that because trAXIN2 does not contain the DIX domain,
the trAXIN2 protein interactions with trAXIN2 or full-length AXIN2 are
likely not direct but are instead facilitated by another protein in the
destruction complex that contains AXIN binding sites, such as APC [3].
Interactions of trAXIN2 and full-length AXIN2 with AXIN1 were also
tested, because AXIN1 is a component of the β-catenin destruction
complex, and AXIN1 contains a DIX domain that may dimerize with
AXIN2 and other AXIN1 molecules. Interestingly, IP of AXIN1 led to
the recovery of a greater amount of wild-type AXIN2 protein than with
the trAXIN2 protein (Figure 3C ), despite lower expression of AXIN2 in
HEK293T cells (Figure 3A). This observation suggests that much of the
AXIN1-AXIN2 protein interactions detected in the IP assay may reflect
direct interaction (i.e., heterodimerization), while the AXIN1-trAXIN2
interaction may be an indirect interaction mediated by APC and/or other
proteins. Finally, both AXIN2 and trAXIN2 proteins were found toIB: FLAG
IB: mycAXIN2
trAXIN2
AXIN2
trAXIN2
AXIN2:FLAG + + - -
AXIN2:myc + - + +
trAXIN2:FLAG - - + -
trAXIN2:myc - + - +
Input:
A B
IP: FLAG (AXIN1) 
AXIN1 + +
AXIN2 + -
trAXIN2 - +
IB: AXIN2
β
IBAXIN2trAXIN2
C D
Figure 3. The trAXIN2 protein is present in complexes with AXIN2, A
indicated FLAG- or myc-tagged expression constructs. The expression
was assessed in IB assays to address the levels of the proteins in th
with the indicated plasmids. IPs were carried out with the indicated
antibody in C and D (for AXIN1-FLAG and β-catenin–FLAG, respective
trAXIN2, AXIN2, AXIN1, and β-catenin. FLAG–β-catenin IPs (D) were
destruction complexes.complex with β-catenin, demonstrating that the trAXIN2 protein is
present in β-catenin protein-containing complexes (Figure 3D).
Expression of trAXIN2 Inhibits Colony Formation in an
APC-Mutant CRC Cell Line
It has previously been shown that small molecules that stabilize the
AXIN1 and AXIN2 proteins, such as the XAV939 tankyrase
inhibitor, can inhibit the in vitro proliferation and/or survival of
some CRC cell lines with APC mutations [33,39]. We sought to
determine if the trAXIN2 protein retains this ability to inhibit the
growth and/or survival of the SW480 CRC cell line, which has
constitutively activated Wnt signaling due to APC mutational
inactivation [40]. We also studied the effects of the trAXIN2 protein
in the RKO CRC cell line, as it lacks mutations in APC, CTNNB1,
or other Wnt pathway factors and it displays no evidence of activated
Wnt pathway signaling [41]. These two cell lines were transfected
with empty (control) vector, AXIN2, or trAXIN2 expression
constructs that also encode resistance to geneticin (G418). After 21
days of G418 selection, the resultant colonies were stained and
counted. Similar to the effects seen with wild-type AXIN2, trAXIN2
inhibited colony formation in the SW480 cell line (Figure 4, A and B).
The somewhat more potent activity of trAXIN2 in inhibiting SW480
colony formation may result from the higher expression levels of the
trAXIN2 protein relative to AXIN2 at early time points after
transfection, based on the observed higher expression of trAXIN2
relative to wild-type AXIN2 in the transient transfection assays inIP: myc
IB: FLAG
AXIN2:FLAG - + + -
AXIN2:myc + + - -
trAXIN2:FLAG + - - +
trAXIN2:myc - - + +
AXIN2
trAXIN2
IP: FLAG (β-catenin)
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AXIN2
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XIN1, and β-catenin. (A) HEK293T cells were transfected with the
of the FLAG- and myc-epitope–tagged AXIN2 and trAXIN2 proteins
e input material used for IP. (B–D) HEK293T cells were transfected
antibodies: anti–myc-epitope antibody in B and anti-FLAG-epitope
ly), with the studies showing that trAXIN2 can form complexes with
performed following treatment with MG132 to stabilize β-catenin
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observe inhibition of G418-resistant colony formation with wild-type
AXIN2 or trAXIN2 (Figure 4, C andD), consistent with the absence of
inhibitory effects on RKO cell proliferation and/or survival in published
studies with the XAV939 tankyrase inhibitor that stabilizes AXIN1/2
[33]. Interestingly, when selected resultant G418-resistant colonies of
SW480 cells were harvested at day 14 after G418 selection and analyzed
by IB, detectable expression of trAXIN2 but not wild-type AXIN2 was
seen in harvested colonies (Figure 4E and data not shown). These findings
suggest that when acutely overexpressed, the trAXIN2 and wild-type
AXIN2 proteins may have similar inhibitory effects inAPC-mutant colon
cancer cells. However, when stably and more modestly expressed in
APC-mutant CRC cells, a potential loss-of-function of the trAXIN2
protein in CRC growth suppression may be revealed.pCMV-3Tag AXIN2 trAXIN2 
pCMV-3Tag AXIN2      trAXIN2
A
B
*
*
* p-value <0.05
60
40
20
0
N
um
be
r o
f c
ol
on
ie
s
SW-480 colony formation, 21 days
pC
MV
-3T
ag
pC
MV
-3T
ag
-AX
IN2
pC
MV
-3T
ag
-trA
XIN
2
Figure 4. AXIN2 and trAXIN2 inhibit G418-resistant colony formatio
formation assays were undertaken in the APCmutant SW480 CRC ce
APC or CTNNB1 (C and D). SW480 and RKO cells were transfected wit
G418 drug selection for 21 days, and then the cells were fixed and sta
C); experiments were undertaken three separate times to quantify co
indicated expression plasmids and grown under G418 selection for
antibody to assess AXIN2 and trAXIN2 protein expression.trAXIN2 Effects on β-Catenin/TCF-Dependent Reporter Gene
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One of the primary functions of the AXIN proteins is to promote the
turnover of β-catenin, thereby inhibiting the expression of downstream
Wnt/β-catenin/TCF-regulated target genes. As expected, Wnt3a
treatment of HEK293T cells was found to increase the activity of the
well-characterized TCF-dependent luciferase reporter construct, TOP-
Flash, by roughly nine-fold (Figure 5A). Transient transfection and
ectopic overexpression of the wild-type AXIN2 and trAXIN2 proteins
potently inhibited TOPFlash reporter gene activity, reducing the
Wnt3a-induced reporter gene activity back to the baseline level seen in
the non–Wnt3a-treated cells. To assess the effect of the wild-type
and trAXIN2 proteins on endogenous target genes when the proteins
were expressed at potentially more physiological levels, we generatedpCMV-3Tag AXIN2 trAXIN2 
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with an empty retroviral expression vector or with retroviral constructs
encoding wild-type AXIN2 or trAXIN2 and assessed the levels of the
transduced AXIN2 proteins using an anti-FLAG epitope antibody
(Figure 5B). We then assessed the effects of Wnt3a treatment on
expression of multiple candidate Wnt/β-catenin/TCF target genes,
including Axin2, Lgr5, Nkd1, Bmp4, Irs1, and Edn1 [42]. The genes
most potently induced byWnt3a treatment were Axin2 and Lgr5, with
roughly 20-fold and 10-fold induction, respectively, whereas the other
four genes studied were much more modestly induced by Wnt
treatment. AXIN2 overexpression was moderately to significantly active
in inhibiting the Wnt3a-induced expression of all six target genes
(Figure 5C ). In contrast, trAXIN2 showed negligible, if any, ability to
inhibit Wnt-mediated induction of any of the six target genes
(Figure 5C ). Curiously, IEC-6 cells stably overexpressing the trAXIN2
protein showed enhanced Lgr5 gene expression in response to Wnt3a
treatment (Figure 5C ). The basis for the apparent ability of the trAXIN2
protein to enhance Lgr5 expression in the IEC-6 cells in response to
Wnt3a treatment is not known but is consistent with the notion that theA
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Discussion
We studied the consequences of the AXIN2 1989GNA (W663X)
mutation on AXIN2 protein function using the predicted trAXIN2
protein in cell culture–based assays to assess how its function might
contribute to CRC development. The 1989GNA AXIN2 mutation
segregates with oligodontia and colorectal neoplasia in an autosomal
dominant manner [21]. Whether the mutation influences cancer
development through a gain-of-function or a loss-of-function
mechanism, or perhaps through both mechanisms, is not yet
understood. If the AXIN2 1989GNA allele mRNA was susceptible
to NMD, then it would point to a loss-of-function mechanism in
colon neoplasia, consistent with the current, more widely held notion
that AXIN proteins act as tumor suppressors [19]. However,
transcripts from both the wild-type and 1989GNA alleles were
detected in PBLs from a heterozygous 1989GNA carrier, suggesting
that the 1989GNA allele can encode a trAXIN2 protein product inAXIN2
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Neoplasia Vol. 17, No. 5, 2015 Effects of AXIN2 on AXIN2 Protein Function Mazzoni et al. 471patient cells. IP studies found that, like wild-type AXIN2, the
trAXIN2 protein was present in complexes containing β-catenin as
well as AXIN2, trAXIN2, and AXIN1. However, while the trAXIN2
protein retains these interactions, unlike wild-type AXIN2, trAXIN2
likely does not dimerize with the AXIN1 and AXIN2 proteins,
because of the absence of the C-terminal DIX domain in trAXIN2.
Our transient transfection studies revealed that the trAXIN2 protein
was expressed at higher levels than wild-type AXIN2. The expression
difference may reflect differences in the mechanisms regulating
trAXIN2 stability, as evidenced by the reduction in wild-type AXIN2
but not trAXIN2 protein in transiently transfected HEK293T cells
treated with the GSK3β inhibitor, BIO. Like wild-type AXIN2,
trAXIN2 potently inhibited the Wnt3a-mediated induction of the
TCF reporter, TOPFlash, when highly expressed in transient
transfection assays in HEK293T cells. However, when stably
expressed at more moderate levels in IEC-6 cell lines, the trAXIN2
protein lacked the ability to inhibit Wnt3a-mediated activation of
endogenous Wnt/β-catenin/TCF target genes. Similarly, trAXIN2
was just as effective as wild-type AXIN2 in inhibiting colony
formation in APC-mutant SW480 CRC cells, with AXIN2-mediated
growth inhibition and/or apoptosis likely resulting from acute effects
of overexpression. However, when selected drug-resistant SW480
colonies resulting from transfection were expanded over 14 days,
stable expression of trAXIN2 but not wild-type AXIN2 could be seen.
Taken together, our studies and data suggest that the AXIN2
1989GNA mutation is unlikely to have a simple loss-of-function role
in colon neoplasia. Rather, the trAXIN2 protein appears to have
reduced or absent function in regulating the canonical Wnt pathway
when AXIN2 levels are low to moderate, which might be akin to the
situation in cells lacking mutations in the canonical Wnt pathway,
such as APC mutations. When the 1989GNA allele is highly
expressed, such as in CRC cells with constitutive Wnt pathway
activation, the trAXIN2 protein might be highly expressed and might
otherwise have a function akin to those of wild-type AXIN2 in the
canonical Wnt signaling pathway. However, because of its higher
levels of expression than wild-type AXIN2 in certain contexts, the
trAXIN2 protein could have potential gain-of-function effects, such
as in CRC cells with APC mutations or other downstream defects
(e.g., mutations affecting β-catenin). These gain-of-function effects
for trAXIN2 might be expected to predominantly affect the non-Wnt
pathways in which the AXIN1 protein has been shown to function,
such as the extracellular signal-regulated kinase (ERK) [43] or c-Jun
N-terminal kinase (JNK) pathways [44] or in regulation of GSK3β
[45]. In fact, some studies have suggested that high levels of AXIN2
can promote tumor invasion and progression in certain contexts,
including in CRC cells [45,46]. A possible means by which high
levels of AXIN2 may promote cancer cell invasion is by the ability of
AXIN2 to inhibit GSK3β, leading to stabilization of the Snail
transcription factor and the resultant induction of epithelial-
mesenchymal transition by Snail’s role in transcriptional repression
[45]. Hence, it is possible that the trAXIN2 protein could contribute
to colon neoplasia through a gain-of-function effect in initiated colon
neoplastic cells, perhaps due to elevated expression of a trAXIN2
protein that inhibits GSK3β and stabilizes Snail and/or mediates
effects on other known AXIN-regulated pathways, such as ERK or
JNK signaling.
In spite of the ability of trAXIN2 to function in an analogous
fashion to wild-type AXIN2 in some assays when overexpressed, our
findings clearly highlight differences in the regulation and function ofthe two proteins. A possible contributing mechanism that could alter
the stability and/or function of trAXIN2 is that loss of the AXIN2
C-terminus creates a functionally significant change in its protein
conformation. A recent study suggested the N- and C-terminal
regions of AXIN1 interact to form a protected, “closed” conformation
that prevents association of AXIN1 with LRP5/6 [47]. This “closed”
conformation of AXIN1 acts to inhibit Wnt signal transduction. This
interaction between the N- and C-termini, if conserved in the AXIN2
protein, would be predicted to be abolished for the trAXIN2 protein,
perhaps leading to an increased likelihood that a trAXIN2 protein
molecule is in an “open” conformation and inactive in the inhibition
of Wnt signaling.
As negative regulators of Wnt signaling, the AXIN proteins promote
the assembly of complexes that target β-catenin for degradation. As such,
the classic view of the AXIN proteins is that they function as tumor
suppressors through inhibition of Wnt signaling [19]. However, the
mutational evidence to support their role as tumor suppressor genes in
cancer in general and CRC specifically is limited [19]. While the Axin2-
null mouse has no reported cancer phenotype, studies with mammary
stem cells have shown that Axin2-null cells have a more sustained
response to Wnt ligands and that Axin2-null mammary stem cells
outcompete wild-type cells to repopulate the mammary fat pad [48].
Additionally, stabilization of AXIN1 andAXIN2 proteins in breast cancer
cell lines inhibited Wnt signaling, migration, and under low serum
conditions, reduced colony formation [49]. Moreover, using a
wound-healing model, it was shown that Axin2-null mice display
increased Wnt signaling and cell proliferation and decreased cell death,
when compared to heterozygous mice [50]. As such, the loss-of-AXIN2
function remains a potential contributingmechanism for theAXIN2GNA
allele in predisposition to neoplasia. However, increased stability and
effects of trAXIN2 on non-Wnt factors and pathways, such as
GSK3β-dependent phosphorylation of targets, such as Snail, or ERK
and JNK signaling, may have profound effects on promoting the
progression of initiated colon lesions that harbor APC or other Wnt
pathway defects that lead to elevatedAXIN2 gene expression. The data in
this paper highlight the potential role of complex and context-dependent
trAXIN2 function in tumorigenesis. Additional studies, perhaps using
mousemodels, will likely be needed to advance further our understanding
of how the trAXIN2 protein contributes to colon neoplasia.
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